The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kalinin R.E.

Ryazan State Medical University

Suchkov I.A.

Ryazan State Medical University

Mzhavanadze N.D.

Pavlov Ryazan State Medical University

Povarov V.O.

Pavlov Ryazan State Medical University

Hemostatic system in patients with cardiovascular implantable electronic devices

Authors:

Kalinin R.E., Suchkov I.A., Mzhavanadze N.D., Povarov V.O.

More about the authors

Journal: Russian Journal of Cardiology and Cardiovascular Surgery. 2021;14(4): 292‑299

DOI: 10.17116/kardio202114041292

Read: 3104 times

Download PDF (RU)
Contact the author
Table of contents

HEMOSTATIC SYSTEM IN PATIENTS WITH CARDIOVASCULAR IMPLANTABLE ELECTRONIC DEVICES
HEMOSTATIC SYSTEM IN PATIENTS WITH CARDIOVASCULAR IMPLANTABLE ELECTRONIC DEVICES

To cite this article:

Kalinin RE, Suchkov IA, Mzhavanadze ND, Povarov VO. Hemostatic system in patients with cardiovascular implantable electronic devices. Russian Journal of Cardiology and Cardiovascular Surgery. 2021;14(4):292‑299. (In Russ.)
https://doi.org/10.17116/kardio202114041292

Подписка 2026 Кардиология и сердечно-сосудистая хирургия (Russian Journal of Cardiology and Cardiovascular Surgery)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Possibilities of using meldonium as part of complex therapy in patients with ischemic heart disease and chro­nic heart failure combined with obesity. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(1):53-60
Mito­chondrial cyto­protectors in complex therapy of chro­nic heart failure in patients with meta­bolic syndrome or type 2 diabetes mellitus: suba­nalysis of the INDI­KOR study. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(5):566-576
Diaphragm dysfunction as a prognostic criterion of exte­rnal respiratory impairment and nece­ssary extracorporeal membrane oxygenation in patients with chro­nic heart failure. Russian Journal of Anesthesiology and Reanimatology. 2024;(6):38-45
The pote­ntials of the six-minute walking test in clinical practice auto­matization and adva­nced features. Russian Journal of Preventive Medi­cine. 2024;(12):122-127
The role of quantitative body composition analysis in popu­lation in the asse­ssment and moni­toring of cardiovascular risk meta­bolic factors. Russian Journal of Preventive Medi­cine. 2024;(12):128-134
Clinical and phenotypical profiles of patients with chro­nic heart failure with preserved ejection fraction. Russian Journal of Preventive Medi­cine. 2025;(1):83-88
The effect of the iron III poly­saccharide complex use on the cyto­kines, natriuretic peptide and erythropoietin levels in patients with chro­nic heart failure acco­mpanied with anemia. Russian Journal of Preventive Medi­cine. 2025;(3):80-86
Prognostic significance of NT-proBNP and sST2 in patients with chro­nic heart failure and redu­ced ejection fraction after previous deco­mpensation. Russian Cardiology Bulletin. 2025;(1):49-56
Dyna­mics of vector electrocardiography para­meters in patients with chro­nic heart failure under opti­mal drug therapy. Russian Cardiology Bulletin. 2025;(1):57-63
Clinical markers of inflammation and myocardial remo­deling in patients with chro­nic obstructive pulmonary diseases and chro­nic heart failure. Russian Journal of Preventive Medi­cine. 2025;(11):72-78
Abstract:

Hemostatic system is an important human biological system persisting in dynamic equilibrium. Various diseases and conditions can disrupt this balance and result hyper- and hypocoagulation followed by thrombotic and hemorrhagic complications, respectively. Patients with cardiovascular implantable electronic devices (CIED) are currently a large group of cardiac patients. Most of them have chronic heart failure (CHF) due to arrhythmia, coronary artery disease, hypertension and other diseases before implantation. Patients with CHF are characterized by hypercoagulation and advanced risk of thromboembolic and cardiovascular complications. Arrhythmia as one of the parts in pathogenesis of heart failure is eliminated after surgery. Analysis of the impact of CIED implantation on hemostatic system in early and delayed postoperative period is a task of modern medicine. This objective is aimed at searching for risk factors, diagnosis and prediction of thromboembolic and cardiovascular events in this group of patients.

Keywords:

hemostatic system
coagulation
cardiovascular implantable electronic devices
pacing
chronic heart failure

Authors:

Kalinin R.E.

Ryazan State Medical University

Suchkov I.A.

Ryazan State Medical University

Mzhavanadze N.D.

Pavlov Ryazan State Medical University

Povarov V.O.

Pavlov Ryazan State Medical University

Received:

05.11.2020

Accepted:

03.03.2021

Close metadata

References:

  1. Chan AK, Paredes N. The coagulation system in humans. Methods Mol Biol. 2013;992:3-12.  https://doi.org/10.1007/978-1-62703-339-8_1
  2. Musinov IM. Hemostasis system. Vestnik rossijskoj voenno-medicinskoj akademii. 2016;3;55:167-170. (In Russ.).
  3. Smith SA, Travers RJ, Morrissey JH. How it all starts: Initiation of the clotting cascade. Crit Rev Biochem Mol Biol. 2015;50;4:326-336.  https://doi.org/10.3109/10409238.2015.1050550
  4. Furlan M. Sticky and promiscuous plasma proteins maintain the equilibrium between bleeding and thrombosis. Swiss Med Wkly. 2002;132(15-16):181-189. 
  5. Palta S, Saroa R, Palta A. Overview of the coagulation system. Indian J Anaesth. 2014;58(5):515-523.  https://doi.org/10.4103/0019-5049.144643
  6. Atreya AR, Cook JR, Lindenauer PK. Complications arising from cardiac implantable electrophysiological devices: review of epidemiology, pathogenesis and prevention for the clinician. Postgrad Med. 2016;128(2):223-230.  https://doi.org/10.1080/00325481.2016.1151327
  7. Mond HG, Proclemer A. The 11th world survey of cardiac pacing and implantable cardioverter-defibrillators: calendar year 2009--a World Society of Arrhythmia’s project. Pacing Clin Electrophysiol. 2011;34(8):1013-1027. https://doi.org/10.1111/j.1540-8159.2011.03150.x
  8. Raatikainen MJP, Arnar DO, Merkely B, Nielsen JC, Hindricks G, Heidbuchel H, Camm J. A Decade of Information on the Use of Cardiac Implantable Electronic Devices and Interventional Electrophysiological Procedures in the European Society of Cardiology Countries: 2017 Report from the European Heart Rhythm Association. Europace. 2017;19(suppl 2):1-90.  https://doi.org/10.1093/europace/eux258
  9. Kushakovskij MS, Grishkin JuN. Aritmii serdca (Rasstrojstva serdechnogo ritma i narushenija provodimosti. Prichiny, mehanizmy, jelektrokardiograficheskaja i jelektrofiziologicheskaja diagnostika, klinika, lechenie). Rukovodstvo dlja vrachej. SPb: OOO «Izdatel’stvo Foliant»; 2017. (In Russ.).
  10. Kivva VN, Abramova TN. Patogenez serdechnoj nedostatochnosti. Astrahanskij medicinskij zhurnal. 2009;4(1):73-81. (In Russ.).
  11. Fleischmann KE, Orav EJ, Lamas GA, Mangione CM, Schron E, Lee KL, Goldman L. Pacemaker implantation and quality of life in the Mode Selection Trial (MOST). Heart Rhythm. 2006;3(6):653-659.  https://doi.org/10.1016/j.hrthm.2006.02.1031
  12. Udo EO, van Hemel NM, Zuithoff NP, Nijboer H, Taks W, Doevendans PA, Moons KG. Long term quality-of-life in patients with bradycardia pacemaker implantation. Int J Cardiol. 2013;168(3):2159-2163. https://doi.org/10.1016/j.ijcard.2013.01.253
  13. Kalinin RE, Suchkov IA, Mzhavanadze ND, Povarov VO. Application of aquarel questionaire in assessment of quality of life in patients with cardiac implantable electronic devices. Vestnik Nacional’nogo mediko-hirurgicheskogo Centra im. N.I. Pirogova. 2018;13(3):85-88. (In Russ.). https://doi.org/10.25881/BPNMSC.2018.70.61.019
  14. Gould J, Sieniewicz B, Porter B, Sidhu B, Rinaldi CA. Chronic Right Ventricular Pacing in the Heart Failure Population. Curr Heart Fail Rep. 2018;15(2):61-69.  https://doi.org/10.1007/s11897-018-0376-x
  15. Ausubel K, Furman S. The pacemaker syndrome. Ann Intern Med. 1985;103(3):420-429.  https://doi.org/10.7326/0003-4819-103-3-420
  16. Israel CW. The role of pacing mode in the development of atrial fibrillation. Europace. 2006;8(2):89-95.  https://doi.org/10.1093/europace/euj038
  17. Allessie MA, Boyden PA, Camm AJ, Kléber AG, Lab MJ, Legato MJ, Rosen MR, Schwartz PJ, Spooner PM, Van Wagoner DR, Waldo AL. Pathophysiology and prevention of atrial fibrillation. Circulation. 2001;103(5):769-777.  https://doi.org/10.1161/01.cir.103.5.769
  18. Cannan CR, Higano ST, Holmes DR Jr. Pacemaker induced mitral regurgitation: an alternative form of pacemaker syndrome. Pacing Clin Electrophysiol. 1997;20(3Pt1):735-738.  https://doi.org/10.1111/j.1540-8159.1997.tb03895.x
  19. Beck H, Curtis AB. Right Ventricular Versus Biventricular Pacing for Heart Failure and Atrioventricular Block. Curr Heart Fail Rep. 2016;13(5):230-236.  https://doi.org/10.1007/s11897-016-0299-3
  20. Prinzen FW, Hunter WC, Wyman BT, McVeigh ER. Mapping of regional myocardial strain and work during ventricular pacing: experimental study using magnetic resonance imaging tagging. J Am Coll Cardiol. 1999;33(6):1735-1742. https://doi.org/10.1016/s0735-1097(99)00068-6
  21. Prinzen FW, Peschar M. Relation between the pacing induced sequence of activation and left ventricular pump function in animals. Pacing Clin Electrophysiol. 2002;25(4 Pt 1):484-498.  https://doi.org/10.1046/j.1460-9592.2002.00484.x
  22. Revishvili ASh, Bojcov SA, Davtjan KV. Klinicheskie rekomendacii po provedeniju jelektrofiziologicheskih issledovanij, kateternoj abljacii i primeneniju implantiruemyh ustrojstv. M.: GJeOTAR-MEDIA; 2017. (In Russ.).
  23. Barold SS, Ovsyshcher IE. Pacemaker-induced mitral regurgitation. Pacing Clin Electrophysiol. 2005;28(5):357-360.  https://doi.org/10.1111/j.1540-8159.2005.09486.x
  24. Vernooy K, Dijkman B, Cheriex EC, Prinzen FW, Crijns HJ. Ventricular remodeling during long-term right ventricular pacing following His bundle ablation. Am J Cardiol. 2006;97(8):1223-1227. https://doi.org/10.1016/j.amjcard.2005.11.044
  25. Barold SS, Israel CW. The changing landscape of cardiac pacing. Herzschrittmacherther Elektrophysiol. 2015;26(1):32-38.  https://doi.org/10.1007/s00399-014-0346-2
  26. Deshmukh P, Casavant DA, Romanyshyn M, Anderson K. Permanent, direct His-bundle pacing: a novel approach to cardiac pacing in patients with normal His-Purkinje activation. Circulation. 2000;101(8):869-877.  https://doi.org/10.1161/01.cir.101.8.869
  27. Barba-Pichardo R, Moriña-Vázquez P, Fernández-Gómez JM, Venegas-Gamero J, Herrera-Carranza M. Permanent His-bundle pacing: seeking physiological ventricular pacing. Europace. 2010;12(4):527-533.  https://doi.org/10.1093/europace/euq038
  28. Sharma PS, Dandamudi G, Naperkowski A, Oren JW, Storm RH, Ellenbogen KA, Vijayaraman P. Permanent His-bundle pacing is feasible, safe, and superior to right ventricular pacing in routine clinical practice. Heart Rhythm. 2015;12(2):305-312.  https://doi.org/10.1016/j.hrthm.2014.10.021
  29. de Cock CC, Giudici MC, Twisk JW. Comparison of the haemodynamic effects of right ventricular outflow-tract pacing with right ventricular apex pacing: a quantitative review. Europace. 2003;5(3):275-278.  https://doi.org/10.1016/s1099-5129(03)00031-x
  30. Zou C, Song J, Li H, Huang X, Liu Y, Zhao C, Shi X, Yang X. Right ventricular outflow tract septal pacing is superior to right ventricular apical pacing. J Am Heart Assoc. 2015;4(4):e001777. https://doi.org/10.1161/JAHA.115.001777
  31. Yu CM, Hayes DL. Cardiac resynchronization therapy: state of the art 2013. Eur Heart J. 2013;34(19):1396-1403. https://doi.org/10.1093/eurheartj/ehs454
  32. Petruhina AA, Tereshhenko SN, Zhirov IV. Modulation of Cardiac Contractility — a New Method in the Treatment of Heart Failure. Racional’naja farmakoterapija v kardiologii. 2016; 12(5):574-581. (In Russ.).
  33. Abraham WT, Kuck KH, Goldsmith RL, Lindenfeld J, Reddy VY, Carson PE, Mann DL, Saville B, Parise H, Chan R, Wiegn P, Hastings JL, Kaplan AJ, Edelmann F, Luthje L, Kahwash R, Tomassoni GF, Gutterman DD, Stagg A, Burkhoff D, Hasenfuß G. A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation. JACC Heart Fail. 2018;6(10):874-883.  https://doi.org/10.1016/j.jchf.2018.04.010
  34. Cugno M, Mari D, Meroni PL, Gronda E, Vicari F, Frigerio M, Coppola R, Bottasso B, Borghi MO, Gregorini L. Haemostatic and inflammatory biomarkers in advanced chronic heart failure: role of oral anticoagulants and successful heart transplantation. Br J Haematol. 2004;126(1):85-92.  https://doi.org/10.1111/j.1365-2141.2004.04977.x
  35. Chung I, Lip GY. Platelets and heart failure. Eur Heart J. 2006;27(22):2623-2631. https://doi.org/10.1093/eurheartj/ehl305
  36. Mehta J, Mehta P. Platelet function studies in heart disease. VI. Enhanced platelet aggregate formation activity in congestive heart failure: inhibition by sodium nitroprusside. Circulation. 1979;60(3):497-503.  https://doi.org/10.1161/01.cir.60.3.497
  37. Kalinin RE, Suchkov IA, Mzhavanadze ND, Povarov VO. Endothelial dysfunction in patients with cardiac implantable electronic devices (literature review). Nauka molodyh (Eruditio Juvenium). 2016;3:84-92. (In Russ.).
  38. Kleber ME, Koller L, Goliasch G, Sulzgruber P, Scharnagl H, Silbernagel G, Grammer TB, Delgado G, Tomaschitz A, Pilz S, März W, Niessner A. Von Willebrand factor improves risk prediction in addition to N-terminal pro-B-type natriuretic peptide in patients referred to coronary angiography and signs and symptoms of heart failure and preserved ejection fraction. Circ Heart Fail. 2015;8(1):25-32.  https://doi.org/10.1161/CIRCHEARTFAILURE.114.001478
  39. Gombos T, Makó V, Cervenak L, Papassotiriou J, Kunde J, Hársfalvi J, Förhécz Z, Pozsonyi Z, Borgulya G, Jánoskuti L, Prohászka Z. Levels of von Willebrand factor antigen and von Willebrand factor cleaving protease (ADAMTS13) activity predict clinical events in chronic heart failure. Thromb Haemost. 2009;102(3):573-580.  https://doi.org/10.1160/TH09-01-0036
  40. Chung I, Choudhury A, Patel J, Lip GY. Soluble, platelet-bound, and total P-selectin as indices of platelet activation in congestive heart failure. Ann Med. 2009;41(1):45-51.  https://doi.org/10.1080/07853890802227089
  41. Moskalets OV. Molecules of cellular adhesion ICAM-1 and VCAM-1 in infectious pathology. Pacific Medical Journal. 2018;(2):21-25. (In Russ.). https://doi.org/10.17238/PmJ1609-1175.2018.2.21-25
  42. Kalinin RE, Suchkov IA, Klimentova JeA, Egorov AA, Povarov VO. Apoptosis in vascular pathology: present and future. Rossijskij mediko-biologicheskij vestnik im. akad. I.P. Pavlova. 2020;28(1):79-87. (In Russ.). https://doi.org/10.23888/PAVLOVJ202028179-87
  43. Jafri SM, Ozawa T, Mammen E, Levine TB, Johnson C, Goldstein S. Platelet function, thrombin and fibrinolytic activity in patients with heart failure. Eur Heart J. 1993;14(2):205-212.  https://doi.org/10.1093/eurheartj/14.2.205
  44. Badimon L, Martínez-González J, Royo T, Lassila R, Badimon JJ. A sudden increase in plasma epinephrine levels transiently enhances platelet deposition on severely damaged arterial wall — studies in a porcine model. Thromb Haemost. 1999;82(6):1736-1742.
  45. Shmeleva VM, Semenova ON, Papajan LP, Jagoshkina SI. Activation of haemostasis in patients with chronic heart failure. Vestnik Sankt-Peterburgskogo universiteta. 2009;11(1):37-43. (In Russ.).
  46. Hsu CC, Fu TC, Huang SC, Wang JS. High-intensity interval training recuperates capacity of endogenous thrombin generation in heart failure patients with reduced ejection fraction. Thromb Res. 2020;187:159-165.  https://doi.org/10.1016/j.thromres.2020.01.013
  47. Reichman-Warmusz E, Domal-Kwiatkowska D, Matysiak N, Kurek J, Spinczyk D, Dudek D, Helewski K, Wojnicz R. Tissue factor is unregulated in microvascular endothelial cells of patients with heart failure. J Clin Pathol. 2016;69(3):221-225.  https://doi.org/10.1136/jclinpath-2015-203172
  48. Chin BS, Blann AD, Gibbs CR, Chung NA, Conway DG, Lip GY. Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure. Eur J Clin Invest. 2003;33(11):941-948.  https://doi.org/10.1046/j.1365-2362.2003.01252.x
  49. Tousoulis D, Antoniades C, Bosinakou E, Kotsopoulou M, Tsioufis C, Tentolouris C, Trikas A, Pitsavos C, Stefanadis C.Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure. Heart. 2005;91(1):27-31.  https://doi.org/10.1136/hrt.2003.027110
  50. Wannamethee SG, Whincup PH, Papacosta O, Lennon L, Lowe GD. Associations between blood coagulation markers, NT-proBNP and risk of incident heart failure in older men: The British Regional Heart Study. Int J Cardiol. 2017;230:567-571.  https://doi.org/10.1016/j.ijcard.2016.12.056
  51. Zabczyk M, Butenas S, Palka I, Nessler J, Undas A. Active tissue factor and activated factor XI in circulating blood of patients with systolic heart failure due to ischemic cardiomyopathy. Pol Arch Med Wewn. 2010;120(9):334-340. 
  52. Bozkurt B. Factor Xa Inhibition, A New Strategy for Prevention of Adverse Cardiac Remodeling in Early Stages? JACC Basic Transl Sci. 2020;5(1):84-87.  https://doi.org/10.1016/j.jacbts.2019.12.008
  53. Jug B, Vene N, Salobir BG, Sebestjen M, Sabovic M, Keber I. Procoagulant state in heart failure with preserved left ventricular ejection fraction. Int Heart J. 2009;50(5):591-600.  https://doi.org/10.1536/ihj.50.591
  54. Mirsaeva GH, Mironchuk NN. Features of coagulation hemostasis and anticoagulation system in patients with chronic heart failure due to ischemic heart disease. Kazanskij medicinskij zhurnal. 2015;96(5):716-722. (In Russ.).
  55. Siliste RN, Antohi EL, Pepoyan S, Nakou E, Vardas P. Anticoagulation in heart failure without atrial fibrillation: gaps and dilemmas in current clinical practice. Eur J Heart Fail. 2018;20(6):978-988.  https://doi.org/10.1002/ejhf.1153
  56. Uhrikova I, Sepsi M, Hlozkova J, Suchy P, Kasajova M, Machackova K, Delev DP, Ciccocioppo R, Kruzliak P, Scheer P. Changes in Hematologic and Coagulation Profiles in Rabbits with Right-ventricle Pacing. Folia Med (Plovdiv). 2016;58(2):89-94.  https://doi.org/10.1515/folmed-2016-0013
  57. Gjesdal G, Hansen AB, Brandes A. Does bipolar pacemaker current activate blood platelets? Pacing Clin Electrophysiol. 2009;32(5):627-631.  https://doi.org/10.1111/j.1540-8159.2009.02336.x
  58. Fazio S, Cittadini A, Sabatini D, Santomauro M, Cocozza M, Oliviero U, Chiariello M, Sacca L. Platelet aggregability in patients with a VVI pacemaker. Pacing Clin Electrophysiol. 1993;16(2):254-256.  https://doi.org/10.1111/j.1540-8159.1993.tb01572.x
  59. Ito T, Tanouchi J, Kato J, Nishino M, Iwai K, Tanahashi H, Hori M, Yamada Y, Kamada T. Prethrombotic state due to hypercoagulability in patients with permanent transvenous pacemakers. Angiology. 1997;48(10):901-906.  https://doi.org/10.1177/000331979704801007
  60. Hingorani A, Ascher E, Yorkovich W, Mazzariol F, Jacob T, Gunduz Y, Salles-Cunha S. Upper extremity deep venous thrombosis: an underrecognized manifestation of a hypercoagulable state. Ann Vasc Surg. 2000;14(5):421-426.  https://doi.org/10.1007/s100169910084
  61. Christopoulou-Cokkinou V, Kourepi-Logotheti, Kontaxis A, Mallios C, Vorides EM, Cokkinos DV. Evidence of low-grade intravascular coagulation in patients with transvenous pacemakers. Pacing Clin Electrophysiol. 1982;5(3):341-344.  https://doi.org/10.1111/j.1540-8159.1982.tb02240.x
  62. Abe H, Takahara K, Nakashima Y, Kuroiwa A. Effect of low dose aspirin on augmented plasminogen activator inhibitor type 1 activity in patients with permanent pacemakers. Pacing Clin Electrophysiol. 1994;17(2):146-151.  https://doi.org/10.1111/j.1540-8159.1994.tb01365.x
  63. Lelakowski J, Domagała TB, Rydlewska A, Januszek R, Kotula Horowitz K, Majewski J, Ząbek A, Małecka B, Musiał J. Effect of selected prothrombotic and proinflammatory factors on the incidence of venous thrombosis after pacemaker implantation. Kardiol Pol. 2012;70(3):260-267. 
  64. Korkeila P, Mustonen P, Koistinen J, Nyman K, Ylitalo A, Karjalainen P, Lund J, Airaksinen J. Clinical and laboratory risk factors of thrombotic complications after pacemaker implantation: a prospective study. Europace. 2010;12(6):817-824.  https://doi.org/10.1093/europace/euq075
  65. Zhang X, Li Y, Wang N, Zhang C, Zhang D, Li Q. Effects of permanent cardiac pacemaker implantation on vascular endothelial function, blood coagulation and cardiac function in patients with bradycardia. Exp Ther Med. 2018;16(6):4717-4721. https://doi.org/10.3892/etm.2018.6808
  66. Ma J, Cui L, Huo W, Wang G, Quan X, Zhang J. Correlation between Deep Venous Thrombosis and Inflammation in Patients after Implantation of Permanent Pacemaker. Iran J Public Health. 2020;49(1):30-36. 
  67. Kalinin RE, Suchkov IA, Mzhavanadze ND, Povarov VO. Dynamics of Coagulation Parameters and Their Relationship with Venous Thromboembolic Events in Patients with Cardiac Implantable Electronic Devices. Flebologiya. 2019;13(1):21-26. (In Russ.). https://doi.org/10.17116/flebo20191301121
  68. Kalinin RE, Suchkov IA, Shitov II, Mzhavanadze ND, Povarov VO. Venous thromboembolism in patients with cardiac implantable electronic devices. Angiologija i sosudistaja hirurgija. 2017;23(4):69-74. (In Russ.).
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.